Tag:"pharmaceutical-benefits-scheme"

Olaparib (Lynparza) for metastatic breast cancer in people with a BRCA gene mutation
Urgent opportunity As some of you may know, BCNA provides a consumer comment to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of drugs being considered for subsidy on the PBS. Equity of access to new treatment options is especially important for those with metastatic breast cancer. Our policy team are currently working on a submission for olaparib (Lynparza) for metastatic breast cancer in people with a BRCA gene mutation. Olaparib is a targeted therapy called a PARP inhibitor. It works by making it hard for cancer cells with a BRCA1 or BRCA2 mutation to survive. If you have accessed olaparib privately or have wanted to access it but were unable to due to it not being subsidised and would like to contribute to the BCNA submission, please contact Julie Rae in our policy team: jrae@bcna.org.au today. We use quotes from real people who have experienced the issue to illustrate the points we make in our submissions. Additionally, if you have a known BRCA 1/2 mutation (regardless of whether you have been recommended olaparib) and would like to contribute, please also contact Julie
Mez_BCNA
10 months ago Place News and events
42Views
1like
0Comments
Trodelvy approved for PBS
BCNA welcomes yesterday's announcement to list Trodelvy® (sacituzumab govitecan) to the Pharmaceutical Benefits Scheme (PBS). Check out the article for full details of this news and eligibility https://www.bcna.org.au/news/2022/03/trodelvy-approved-for-pbs/
Mez_BCNA
4 years ago Place General
121Views
2likes
3Comments
Subsidy for Verzenio (abemaciclib) expanded on the PBS
Hi everyone, I thought some of you may be interested to read about the recent expansion of the Pharmaceutical Benefits Scheme (PBS) listing of Verzenio (abemaciclib) to include its use in combination with Faslodex (fulvestrant). You can read the full details on the BCNA website link below: https://www.bcna.org.au/news/2021/10/subsidy-for-verzenio-abemaciclib-expanded-on-the-pbs/ We recommend talking to your treatment team if you have any questions about abemaciclib or fulvestrant. (This has also been posted in private group 'Living with metastatic breast cancer')
Mez_BCNA
4 years ago Place General
41Views
0likes
0Comments

Foundation partner	Major partners

Olaparib (Lynparza) for metastatic breast cancer in people with a BRCA gene mutation

Trodelvy approved for PBS

Subsidy for Verzenio (abemaciclib) expanded on the PBS